BOSTON SCIENTIFIC CORP

On July 25, 2025, Ellen M. Zane, anindependent member of our Board of Directors, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Ms. Zane’s plan covers the sale of 12,891 shares of our common stock. Transactions under Ms. Zane’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Ms. Zane’s plan will terminate on the earlier of October 23, 2026 or the date all shares subject to the plan have been sold.

On August 28, 2025, Arthur C. Butcher, our Executive Vice President and Group President, MedSurg and Asia Pacific, entered into a new trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Butcher’s plan covers the sale of up to 85,334 shares of our common stock including up to 19,721 shares to be acquired upon determination and/or vesting of performance share units and restricted share units and 57,593 shares of our common stock to be acquired upon exercise of stock options. Transactions under Mr. Butcher’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Butcher’s plan will terminate on the earlier of February 1, 2027, or the date all shares subject to the plan have been sold.

On August 28, 2025, Jeffrey B. Mirviss, our Senior Vice President and President, Peripheral Interventions, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Mirviss’ plan covers the sale of up to 86,510 shares of our common stock including up to 53,572 shares to be acquired upon determination and/or vesting of performance share units and restricted share units and 32,938 shares of our common stock to be acquired upon exercise of stock options. Transactions under Mr. Mirviss’ plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Mirviss’ plan will terminate on the earlier of February 27, 2026 or the date all shares subject to the plan have been sold.

On August 29, 2025, Michael F. Mahoney, our Chairman and Chief Executive Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Mahoney’s plan covers the sale of 478,914 shares of our common stock, including 287,264 shares to be acquired upon exercise of stock options. Transactions under Mr. Mahoney’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Mahoney’s plan will terminate on the earlier of April 17, 2026, or the date all shares subject to the plan have been sold.